NVCR
NovoCure Limited NASDAQ Listed Oct 1, 2015$16.84
Mkt Cap $2.0B
52w Low $9.82
68.6% of range
52w High $20.06
50d MA $12.53
200d MA $12.56
P/E (TTM)
-13.6x
EV/EBITDA
-13.7x
P/B
5.4x
Debt/Equity
0.8x
ROE
-40.0%
P/FCF
-19.0x
RSI (14)
—
ATR (14)
—
Beta
0.82
50d MA
$12.53
200d MA
$12.56
Avg Volume
1.9M
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
No. 4 The Forum · Saint Helier JE2 4UF · JE
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | BMO | -0.51 | -0.62 | -21.0% | 11.93 | +12.0% | +27.5% | +9.3% | +1.9% | -6.2% | +3.9% | — |
| Feb 26, 2026 | BMO | -0.41 | -0.22 | +46.3% | 14.99 | -11.6% | -8.3% | -0.6% | -1.1% | -1.6% | +0.9% | — |
| Oct 30, 2025 | BMO | -0.42 | -0.33 | +21.4% | 13.48 | +0.0% | -4.9% | -0.1% | -4.5% | -1.9% | -3.2% | — |
| Jul 24, 2025 | BMO | -0.39 | -0.36 | +7.7% | 16.51 | -0.1% | -24.0% | -4.0% | -3.3% | -2.2% | -3.6% | — |
| Apr 24, 2025 | BMO | -0.47 | -0.31 | +34.0% | 17.77 | +6.6% | +4.4% | -0.3% | -1.0% | -0.1% | -0.8% | — |
| Feb 27, 2025 | BMO | -0.34 | -0.61 | -79.4% | 21.96 | -8.4% | -12.4% | -0.8% | -3.5% | -1.2% | +5.3% | — |
| Oct 30, 2024 | BMO | -0.34 | -0.28 | +17.6% | 16.89 | -0.7% | +0.6% | -10.7% | +6.6% | +2.5% | +0.2% | — |
| Jul 25, 2024 | BMO | -0.40 | -0.31 | +22.5% | 18.79 | +0.0% | -0.7% | +2.0% | +9.4% | +12.3% | -2.5% | — |
| May 2, 2024 | BMO | -0.43 | -0.36 | +16.3% | 12.74 | +5.1% | +11.4% | +4.2% | +5.2% | -0.1% | +3.2% | — |
| Feb 22, 2024 | BMO | -0.53 | -0.45 | +15.1% | 15.62 | +8.7% | -2.4% | -0.1% | -2.1% | +9.4% | -1.7% | — |
| Oct 26, 2023 | BMO | -0.52 | -0.46 | +11.5% | 14.08 | +2.8% | -7.5% | -2.9% | +3.3% | +1.8% | -1.5% | — |
| Jul 27, 2023 | BMO | -0.50 | -0.54 | -8.0% | 40.34 | +0.0% | -15.9% | -1.8% | -2.0% | +0.0% | -7.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Evercore ISI | Maintains | Outperform → Outperform | — | $15.21 | $15.48 | +1.8% | +9.3% | +1.9% | -6.2% | +3.9% | +2.0% |
| Apr 16 | Wedbush | Maintains | Neutral → Neutral | — | $12.17 | $12.24 | +0.6% | +3.7% | +1.7% | -1.2% | -3.5% | +6.5% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.99 | $13.25 | -11.6% | -8.3% | -0.6% | -1.1% | -1.6% | +0.9% |
| Feb 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.50 | $14.40 | +37.1% | +19.3% | -12.3% | +1.3% | +2.4% | -0.1% |
| Jan 15 | Wedbush | Maintains | Neutral → Neutral | — | $13.77 | $13.79 | +0.1% | +0.2% | -1.2% | -4.5% | +4.1% | +4.6% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.18 | $13.86 | -2.3% | -3.7% | +0.9% | +0.2% | -1.2% | -4.5% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.48 | $13.48 | +0.0% | -4.9% | -0.1% | -4.5% | -1.9% | -3.2% |
| Oct 27 | JP Morgan | Maintains | Neutral → Neutral | — | $13.75 | $13.75 | +0.0% | -1.2% | -1.5% | +0.8% | -4.9% | -0.1% |
| Jul 25 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $12.54 | $12.73 | +1.5% | -4.0% | -3.3% | -2.2% | -3.6% | +5.5% |
| Jun 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $17.10 | $17.19 | +0.5% | +5.3% | -1.1% | +0.4% | +0.0% | -1.0% |
| Apr 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.51 | $17.00 | +3.0% | +7.6% | +4.4% | -0.3% | -1.0% | -0.1% |
| Apr 16 | Wedbush | Maintains | Neutral → Neutral | — | $16.46 | $15.96 | -3.0% | -3.8% | -1.6% | +0.0% | +6.0% | +7.6% |
| Apr 10 | JP Morgan | Maintains | Neutral → Neutral | — | $16.95 | $16.77 | -1.1% | -5.1% | +2.6% | +0.3% | -0.5% | -3.8% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.38 | $27.22 | -0.6% | -4.2% | +0.5% | -1.3% | +0.6% | +3.0% |
| Dec 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $30.06 | $31.22 | +3.9% | +11.1% | -5.0% | +1.1% | -1.7% | -3.6% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.85 | $29.15 | -2.3% | +2.2% | -4.2% | -9.0% | +5.1% | +2.5% |
| Dec 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.04 | $28.25 | +41.0% | +49.0% | +2.2% | -4.2% | -9.0% | +5.1% |
| Dec 2 | Evercore ISI | Upgrade | In Line → Outperform | — | $20.04 | $28.25 | +41.0% | +49.0% | +2.2% | -4.2% | -9.0% | +5.1% |
| Nov 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.86 | $16.97 | +0.7% | +1.4% | +3.7% | +5.9% | -4.8% | +10.1% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.99 | $16.51 | -2.8% | -10.7% | +6.6% | +2.5% | +0.2% | +8.9% |
| Oct 16 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $17.78 | $21.46 | +20.7% | +0.5% | -5.4% | +1.8% | -5.5% | -0.7% |
| Oct 1 | Evercore ISI | Maintains | In Line → In Line | — | $15.63 | $15.33 | -1.9% | -4.7% | +4.1% | -6.2% | +1.2% | -0.7% |
| Jul 26 | Wells Fargo | Maintains | Overweight → Overweight | — | $18.65 | $19.36 | +3.8% | +2.0% | +9.4% | +12.3% | -2.5% | -6.0% |
| Jul 26 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $18.65 | $19.36 | +3.8% | +2.0% | +9.4% | +12.3% | -2.5% | -6.0% |
| Jul 2 | Evercore ISI | Maintains | In Line → In Line | — | $17.35 | $17.44 | +0.5% | -3.2% | +0.4% | -0.5% | -4.6% | +5.1% |
| Jun 4 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $23.89 | $24.29 | +1.7% | -4.5% | +1.4% | -4.2% | -2.9% | -0.2% |
| May 2 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $12.74 | $13.39 | +5.1% | +11.4% | +4.2% | +5.2% | -0.1% | +3.2% |
| Apr 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $14.88 | $14.48 | -2.7% | -1.7% | -3.4% | -3.9% | -6.3% | -2.0% |
| Apr 3 | Wells Fargo | Maintains | Overweight → Overweight | — | $14.39 | $14.08 | -2.2% | +0.2% | -0.9% | -3.8% | +3.2% | +4.9% |
| Mar 27 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $13.07 | $14.78 | +13.1% | +12.0% | +6.8% | -0.9% | -7.1% | +0.2% |
| Mar 19 | JP Morgan | Maintains | Neutral → Neutral | — | $13.82 | $13.84 | +0.1% | -2.0% | +0.7% | +2.3% | -5.3% | -0.1% |
| Mar 12 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $15.99 | $15.90 | -0.6% | -4.4% | -3.1% | -1.4% | -4.3% | -1.1% |
| Feb 23 | Evercore ISI | Maintains | In Line → In Line | — | $15.24 | $15.10 | -0.9% | -0.1% | -2.1% | +9.4% | -1.7% | -4.4% |
| Feb 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.62 | $16.98 | +8.7% | -2.4% | -0.1% | -2.1% | +9.4% | -1.7% |
| Aug 29 | Wells Fargo | Maintains | Overweight → Overweight | — | $18.61 | $18.59 | -0.1% | +8.8% | +8.3% | +0.6% | +1.0% | -3.9% |
| Aug 28 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $29.77 | $19.74 | -33.7% | -37.5% | +8.8% | +8.3% | +0.6% | +1.0% |
| Aug 8 | Piper Sandler | Upgrade | Neutral → Overweight | — | $26.92 | $28.09 | +4.3% | +2.7% | +7.1% | +3.7% | +1.8% | -0.9% |
| Jul 31 | Evercore ISI | Upgrade | Underperform → In Line | — | $33.32 | $33.68 | +1.1% | -2.0% | +0.0% | -7.8% | -3.3% | -1.9% |
| Jul 28 | Wells Fargo | Maintains | Overweight → Overweight | — | $33.93 | $34.20 | +0.8% | -1.8% | -2.0% | +0.0% | -7.8% | -3.3% |
| Jul 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.34 | $40.34 | +0.0% | -15.9% | -1.8% | -2.0% | +0.0% | -7.8% |
| Jun 7 | Wedbush | Upgrade | Underperform → Neutral | — | $47.00 | $48.30 | +2.8% | +3.5% | -6.5% | -6.0% | +3.4% | +2.8% |
| Jun 7 | Piper Sandler | Maintains | Neutral → Neutral | — | $47.00 | $48.30 | +2.8% | +3.5% | -6.5% | -6.0% | +3.4% | +2.8% |
| Jun 6 | Truist | Maintains | Buy → Buy | — | $82.51 | $74.65 | -9.5% | -43.0% | +3.5% | -6.5% | -6.0% | +3.4% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $82.51 | $74.65 | -9.5% | -43.0% | +3.5% | -6.5% | -6.0% | +3.4% |
| May 16 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $77.82 | $82.00 | +5.4% | +3.6% | -2.7% | +1.4% | -0.1% | +1.7% |
| May 5 | Truist | Maintains | Buy → Buy | — | $66.74 | $66.79 | +0.1% | +2.2% | +1.7% | +0.9% | +2.1% | +2.4% |
| May 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $65.94 | $64.50 | -2.2% | +1.2% | +2.2% | +1.7% | +0.9% | +2.1% |
| Mar 17 | JP Morgan | Downgrade | Neutral → Underweight | — | $64.43 | $59.02 | -8.4% | -11.4% | +2.4% | +0.5% | -3.9% | +0.7% |
| Jan 17 | Piper Sandler | Maintains | Neutral → Neutral | — | $93.99 | $93.00 | -1.1% | -1.8% | +0.6% | -5.2% | +0.5% | -0.5% |
| Jan 6 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $118.81 | $114.15 | -3.9% | -8.2% | -16.3% | +2.0% | +3.9% | -1.0% |
No insider trades available.
8-K
NovoCure Limited -- 8-K Filing
NovoCure's strong early-year performance across its Tumor Treating Fields commercial and clinical programs positions the company favorably for continued growth in its oncology treatment portfolio.
Apr 30
8-K · 5.02
!!! Very High
NovoCure Limited -- 8-K 5.02: Executive Change
NovoCure's appointment of an executive officer lacks finalized compensation details, creating uncertainty about leadership costs and potential shareholder dilution from equity incentives.
Apr 24
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Novocure's Chief Innovation Officer assumes additional Chief Medical Officer duties, signaling either internal talent confidence or potential cost-cutting that could strain leadership capacity during critical product development phases.
Apr 9
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
NovoCure's PANOVA-4 trial met its primary endpoint with statistically significant disease control improvements, potentially supporting label expansion and driving revenue growth for this cancer treatment platform.
Mar 26
8-K
NovoCure Limited -- 8-K Filing
NovoCure achieved record patient treatment volumes with its Tumor Treating Fields therapy in 2025, signaling strong commercial momentum and market adoption for the cancer treatment technology.
Feb 26
8-K · 7.01
! Medium
NovoCure Limited -- 8-K 7.01: Regulation FD Disclosure
NovoCure's Medicare billing privileges were revoked retroactively to December 2025 due to an administrative re-validation procedural lapse, not performance failure, creating significant revenue uncertainty for the company's core products.
Feb 24
8-K · 7.01
! Medium
NovoCure Limited -- 8-K 7.01: Regulation FD Disclosure
NovoCure's Optune Pax received FDA approval for locally advanced pancreatic cancer treatment alongside chemotherapy, potentially expanding the company's addressable market and revenue opportunities.
Feb 11
8-K · 7.01
! Medium
NovoCure Limited -- 8-K 7.01: Regulation FD Disclosure
NovoCure's Medicare billing privileges were revoked December 17, 2025 due to an administrative re-validation procedural issue, potentially threatening U.S. revenue until the company resolves the CMS compliance matter.
Feb 5
Data updated apr 26, 2026 4:14pm
· Source: massive.com